MEDIA ADVISORY, Oct. 24, 2006 (PRIMEZONE) --
What: Michael Bonney, CEO of Cubist Pharmaceuticals, Inc. (CBST) will preside over the opening bell to celebrate its 10-year listing anniversary on the NASDAQ. Cubist Pharmaceuticals is part of The NASDAQ Biotechnology Index. The NASDAQ Biotechnology Index includes securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Wednesday October 25th, 2006 at 9:30 a.m. EDT Contacts: Eileen McIntyre Senior Director of Corporate Communications 781.860.8533 Cell 339 223 6146 email@example.com NASDAQ MarketSite: Stephanie Lowenthal; 646.441.5220
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Cubist Pharmaceuticals, Inc. (CBST):
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(r) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.